Kebede Begna, MD

Relapsed/Refractory Multiple Myeloma: The IKEMA Study

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Isatuximab + Pom-Dex in Relapsed/Refractory Multiple Myeloma

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Relapsed/Refractory Multiple Myeloma: The ALLIANCE A061202 Study

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial

Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study

Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Chronic-Phase CML: The OPTIC Study

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Relapsed/Refractory Multiple Myeloma: The KarMMa-3 Study

Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic

Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

Team Introductions: MM Experts From UT Southwestern vs Mayo Clinic

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.

Larry Anderson, MD, PhD, FACP;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD